Nuvation Bio Secures $60 Million from Eisai for Taletrectinib Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Nuvation Bio's stock fell 18.91% as it hit a 20-day low amid a slight decline in the Nasdaq-100 and S&P 500 indices.
The company's recent exclusive licensing agreement with Eisai grants Eisai development and commercialization rights for taletrectinib in Europe, providing Nuvation Bio with an upfront payment of approximately $60 million. This collaboration is expected to enhance the drug's global market reach and offer treatment options for patients with ROS1+ NSCLC. Additionally, Nuvation Bio could receive up to €145 million in milestone payments, significantly improving its financial outlook and supporting future research and development efforts.
This partnership not only strengthens Nuvation Bio's position in the oncology market but also highlights the potential for accelerated market access for taletrectinib, which is crucial for the company's growth strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVB
Wall Street analysts forecast NUVB stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.330
Low
8.00
Averages
11.38
High
18.00
Current: 5.330
Low
8.00
Averages
11.38
High
18.00
About NUVB
Nuvation Bio Inc. is a global oncology company. The Company is focused on tackling cancer treatment. Its diverse pipeline includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor, and a drug-drug conjugate (DDC) program. IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor. Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), which is detected in various tumors, including gliomas. Its platform leverages its drug discovery and chemistry expertise to find the minimum target binding sites of drug X and drug Y and fuse them together, while maintaining activity. Its DDCs are designed to selectively bind to intracellular as well as surface cell membrane targets that are expressed more highly in specific target tissues and to potently deliver anti-cancer warheads to these target tissues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuvation Bio Director Increases Stake Amid Share Price Surge
- Insider Buying Signal: Nuvation Bio Director Robert Mashal acquired 25,000 shares on June 9, 2026, for $118,250, indicating his confidence in the company's future, particularly against a backdrop of a 96% share price increase.
- Holding Structure Change: Following this transaction, Mashal's direct holdings remain at zero, while his indirect stake via a trust rises to 225,000 shares, demonstrating his ongoing interest and investment in the company's equity.
- Strong Market Performance: On the trade date, Nuvation Bio shares closed at $4.93, reflecting a 96% increase compared to the same date in 2025, showcasing the company's robust market performance and investor confidence in the oncology sector.
- Future Revenue Expectations: Analysts project Nuvation Bio's revenue to reach nearly $203 million this year, a significant increase from approximately $63 million in 2025, highlighting the company's potential in innovative drug development and market acceptance.
See More
Nuvation Bio Director Increases Stock Holdings
- Director Stock Purchase: Nuvation Bio's Director Robert Mashal purchased 25,000 shares at $4.73 each on June 9, 2026, indicating strong confidence in the company's future, especially as its stock price has nearly doubled over the past 52 weeks.
- FDA-Approved Product Launch: Nuvation launched its first FDA-approved drug, Ibtrozi, for non-small cell lung cancer in July 2025, with over 200 new patients starting treatment each quarter, demonstrating robust market demand that could further drive revenue growth.
- Significant Revenue Projections: Analysts project Nuvation's revenue will reach nearly $203 million in 2026, a substantial increase from approximately $63 million in 2025, reflecting the company's market potential and competitiveness in oncology therapeutics.
- Strategic Investment Context: Mashal, a trained oncologist, actively increasing his stock holdings after joining Nuvation's board signals confidence in the company's trajectory, potentially attracting more investor interest in the firm.
See More
Nuvation Bio to Speak at Jefferies Global Healthcare Conference
- Executive Participation: Nuvation Bio's Founder and CEO, Dr. David Hung, along with CFO Philippe Sauvage, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, where they are expected to discuss the company's latest advancements and strategies in cancer treatment.
- Live Webcast: The fireside chat will be available via live webcast on Nuvation Bio's Investor Relations page, and an archived recording will be accessible for 90 days post-event, ensuring that investors who cannot attend live can still access critical information.
- Company Overview: Founded in 2018, Nuvation Bio focuses on developing therapies that create a profound positive impact on patients' lives, with a diverse pipeline that includes the next-generation ROS1 inhibitor taletrectinib (IBTROZI®) and the brain-penetrant IDH1 inhibitor safusidenib.
- Experienced Leadership: Dr. David Hung, the founder of Nuvation Bio, previously established Medivation, Inc., which successfully launched one of the world's leading prostate cancer medications, highlighting his extensive background and expertise in the biopharmaceutical industry.
See More
Nuvation Bio Reports TRUST-II Study Outcomes for IBTROZI in ROS1+ NSCLC
- Quality of Life Improvement: In the TRUST-II study, 88% of patients reported improved or stable quality of life, indicating IBTROZI's effectiveness in alleviating symptoms, which enhances patient confidence and adherence to treatment.
- Cognitive Function Preservation: The study demonstrated that cognitive function scores remained stable throughout treatment, suggesting that IBTROZI can effectively manage the disease without neurological impairment, aligning with patient expectations for quality of life.
- Rapid Symptom Relief: IBTROZI provides rapid relief from burdensome symptoms such as cough and shortness of breath, enabling patients to maintain normal daily activities during treatment, thereby enhancing their overall life experience.
- FDA Approval and Market Outlook: IBTROZI has received FDA approval for the treatment of ROS1+ NSCLC, and a supplemental New Drug Application is underway, which is expected to further drive market acceptance and sales growth.
See More
Investigation Launched into Nuvation Bio's Corporate Governance
- Investigation Initiated: Purcell & Lefkowitz LLP is investigating Nuvation Bio Inc. to determine if the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder rights.
- Shareholder Rights Focus: The investigation is aimed at Nuvation Bio's shareholders, and those interested in learning more about their rights and options can visit the law firm's website for detailed information.
- Commitment to Legal Services: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty, and other corporate misconduct, demonstrating its expertise in protecting shareholder interests.
- No-Cost Consultation: The law firm offers no-cost consultations, allowing shareholders to directly contact attorneys via phone or email to discuss case details, thereby enhancing shareholder confidence in legal support.
See More
Nuvation Bio's Lung Cancer Therapy Application Accepted by FDA
- FDA Application Acceptance: Nuvation Bio (NUVB) announced on Wednesday that its marketing application for the lung cancer therapy Ibtrozi has been accepted by the U.S. FDA, marking a significant advancement in the company's efforts to expand the drug's indications.
- Indication Expansion: The application aims to provide treatment options for both TKI-naive and TKI-pretreated advanced ROS1-positive non-small cell lung cancer patients, demonstrating the company's commitment to addressing diverse patient needs.
- Key Data Support: This supplemental New Drug Application (sNDA) is backed by 10 months of additional data from the company's TRUST-I and TRUST-II studies, further enhancing the validity and compliance of its market application.
- Target Action Date: The FDA has set a target action date of January 4, 2027, and Nuvation Bio expects to continue advancing its market strategy ahead of this date to ensure a successful launch.
See More
Nuvation Bio Director Increases Stake Amid Share Price Surge
- Insider Buying Signal: Nuvation Bio Director Robert Mashal acquired 25,000 shares on June 9, 2026, for $118,250, indicating his confidence in the company's future, particularly against a backdrop of a 96% share price increase.
- Holding Structure Change: Following this transaction, Mashal's direct holdings remain at zero, while his indirect stake via a trust rises to 225,000 shares, demonstrating his ongoing interest and investment in the company's equity.
- Strong Market Performance: On the trade date, Nuvation Bio shares closed at $4.93, reflecting a 96% increase compared to the same date in 2025, showcasing the company's robust market performance and investor confidence in the oncology sector.
- Future Revenue Expectations: Analysts project Nuvation Bio's revenue to reach nearly $203 million this year, a significant increase from approximately $63 million in 2025, highlighting the company's potential in innovative drug development and market acceptance.
See More
Nuvation Bio Director Increases Stock Holdings
- Director Stock Purchase: Nuvation Bio's Director Robert Mashal purchased 25,000 shares at $4.73 each on June 9, 2026, indicating strong confidence in the company's future, especially as its stock price has nearly doubled over the past 52 weeks.
- FDA-Approved Product Launch: Nuvation launched its first FDA-approved drug, Ibtrozi, for non-small cell lung cancer in July 2025, with over 200 new patients starting treatment each quarter, demonstrating robust market demand that could further drive revenue growth.
- Significant Revenue Projections: Analysts project Nuvation's revenue will reach nearly $203 million in 2026, a substantial increase from approximately $63 million in 2025, reflecting the company's market potential and competitiveness in oncology therapeutics.
- Strategic Investment Context: Mashal, a trained oncologist, actively increasing his stock holdings after joining Nuvation's board signals confidence in the company's trajectory, potentially attracting more investor interest in the firm.
See More
Nuvation Bio to Speak at Jefferies Global Healthcare Conference
- Executive Participation: Nuvation Bio's Founder and CEO, Dr. David Hung, along with CFO Philippe Sauvage, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, where they are expected to discuss the company's latest advancements and strategies in cancer treatment.
- Live Webcast: The fireside chat will be available via live webcast on Nuvation Bio's Investor Relations page, and an archived recording will be accessible for 90 days post-event, ensuring that investors who cannot attend live can still access critical information.
- Company Overview: Founded in 2018, Nuvation Bio focuses on developing therapies that create a profound positive impact on patients' lives, with a diverse pipeline that includes the next-generation ROS1 inhibitor taletrectinib (IBTROZI®) and the brain-penetrant IDH1 inhibitor safusidenib.
- Experienced Leadership: Dr. David Hung, the founder of Nuvation Bio, previously established Medivation, Inc., which successfully launched one of the world's leading prostate cancer medications, highlighting his extensive background and expertise in the biopharmaceutical industry.
See More
Nuvation Bio Reports TRUST-II Study Outcomes for IBTROZI in ROS1+ NSCLC
- Quality of Life Improvement: In the TRUST-II study, 88% of patients reported improved or stable quality of life, indicating IBTROZI's effectiveness in alleviating symptoms, which enhances patient confidence and adherence to treatment.
- Cognitive Function Preservation: The study demonstrated that cognitive function scores remained stable throughout treatment, suggesting that IBTROZI can effectively manage the disease without neurological impairment, aligning with patient expectations for quality of life.
- Rapid Symptom Relief: IBTROZI provides rapid relief from burdensome symptoms such as cough and shortness of breath, enabling patients to maintain normal daily activities during treatment, thereby enhancing their overall life experience.
- FDA Approval and Market Outlook: IBTROZI has received FDA approval for the treatment of ROS1+ NSCLC, and a supplemental New Drug Application is underway, which is expected to further drive market acceptance and sales growth.
See More
Investigation Launched into Nuvation Bio's Corporate Governance
- Investigation Initiated: Purcell & Lefkowitz LLP is investigating Nuvation Bio Inc. to determine if the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder rights.
- Shareholder Rights Focus: The investigation is aimed at Nuvation Bio's shareholders, and those interested in learning more about their rights and options can visit the law firm's website for detailed information.
- Commitment to Legal Services: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty, and other corporate misconduct, demonstrating its expertise in protecting shareholder interests.
- No-Cost Consultation: The law firm offers no-cost consultations, allowing shareholders to directly contact attorneys via phone or email to discuss case details, thereby enhancing shareholder confidence in legal support.
See More
Nuvation Bio's Lung Cancer Therapy Application Accepted by FDA
- FDA Application Acceptance: Nuvation Bio (NUVB) announced on Wednesday that its marketing application for the lung cancer therapy Ibtrozi has been accepted by the U.S. FDA, marking a significant advancement in the company's efforts to expand the drug's indications.
- Indication Expansion: The application aims to provide treatment options for both TKI-naive and TKI-pretreated advanced ROS1-positive non-small cell lung cancer patients, demonstrating the company's commitment to addressing diverse patient needs.
- Key Data Support: This supplemental New Drug Application (sNDA) is backed by 10 months of additional data from the company's TRUST-I and TRUST-II studies, further enhancing the validity and compliance of its market application.
- Target Action Date: The FDA has set a target action date of January 4, 2027, and Nuvation Bio expects to continue advancing its market strategy ahead of this date to ensure a successful launch.
See More
